The studies of mucosal immune responses in Bangladeshi children showed highly significant ALS responses to all the CFs and LTB in 80%–100% of the 24- to 59-month-old toddlers and in 52%–95% of the 12- to 23-month-old children given either one-fourth or one-half dose of ETVAX ± dmLT ( Figure 2A ).
← all excerpts
Mucosal Immune Responses Against an Oral Enterotoxigenic Escherichia coli Vaccine Evaluated in Clinical Trials.
1
—
—